Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics1☆,
Section snippets
Subjects and methods
Twenty-seven normal human subjects who met all the entry criteria were entered into the study. Two of these subjects were dropped from the study for a technical reason (fluorescein concentration out of range of fluorophotometer). The other 25 subjects completed all aspects of the study, and their results are reported here.
The most important inclusion criteria were as follows: normal healthy volunteer, age 21 or older, intraocular pressure inclusive between 12 and 21 mm Hg in both eyes,
Results
The mean age of the 25 subjects who completed the study was 34 years (range, 21 to 48). Twelve of these subjects were men, and 13 were women. The depth of the anterior chamber and the corneal diameter were similar in the study eyes and the control eyes. This subjective finding was confirmed by mean measurements (± SD) of the volume of the anterior chambers: 204 ± 37 μl for the drug-treatment designated eyes and 206 ± 37 μl for the placebo-treatment designated eyes. The mean difference in
Discussion
The clinical studies of AGN 192024 have shown that its ocular hypotensive effects after a single dose last many hours.4 The long steady-state that AGN 192024 produces makes it easy to study its physiologic effects, because there is ample time during which to measure aqueous flow. Thus, a lapse of time between pressure and flow measurements is not critical.
It was noted that the intraocular pressure in the placebo-treated eyes on days 2 and 3 was 10% to 11% lower than on day 1 (baseline) before
References (12)
- et al.
Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2
J Biol Chem
(1997) - et al.
The effects of sleep on circulating catecholamines and aqueous flow in human subjects
Exp Eye Res
(1996) - et al.
Aqueous humor dynamics in patients with diabetes mellitus
Am J Ophthalmol
(1995) - et al.
Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds
Br J Pharmacol
(2000) - Woodward DF, Tang-Liu DDS, Madhu C, et al. Prostaglandin F2α (PGF2α) 1-ethanolamide: a pharmacologically unique local...
- et al.
A novel ocular hypotensive lipidinitial safety and efficacy of AGN 192024
Invest Ophthalmol Vis Sci
(1998)
Cited by (163)
Glaucoma
2022, Comprehensive PharmacologyAqueous Humor Dynamics in Uveitic Eyes
2019, American Journal of OphthalmologyAge-related changes in eye morphology and aqueous humor dynamics in DBA/2J mice using contrast-enhanced ocular MRI
2019, Magnetic Resonance ImagingCitation Excerpt :It can also induce calcium activated potassium currents, which relaxes the TM cells and increases outflow. This has been observed in human subjects manifested by IOP changes with tonography [28–31]. Iris atrophy and pigment dispersion have previously been associated with elevated IOP and degeneration of retinal ganglion cells in the DBA/2J glaucoma mouse model [3,5–8].
Unconventional aqueous humor outflow: A review
2017, Experimental Eye ResearchLong-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
2016, European Journal of Pharmacology
- ☆
This study was supported in part by National Institutes of Health research grant (EY 00634; Dr Brubaker), Bethesda, Maryland; Allergan, Inc, Irvine, California; Research to Prevent Blindness, Inc, New York, New York; and the Mayo Foundation, Rochester, Minnesota.
- 1
Accelerated publication.
- 2
Dr Brubaker is a consultant for Allergan. Drs Carpenter and VanDenburgh and Ms Chen are employees of Allergan.